Rheumatology
Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids
Yeo-Jin Lee, Soo Min Ahn, Seokchan Hong, Ji-Seon Oh, Chang-Keun Lee, Bin Yoo, Yong-Gil Kim
Korean J Intern Med. 2024;39(2):338-346. Published online November 30, 2023
Background/Aims: Systemic lupus erythematosus (SLE) responder index (SRI)-4 response has been achieved with belimumab treatment in patients with moderate disease activity in cornerstone clinical trials and following studies. However, most studies involved patients treated with a mean prednisolone-eq..
|